After seven recurrences, a non-Hodgkin lymphoma patient recounts her treatments over the past two decades.
When Wendy Harpham was diagnosed in 1990, she began treatment with what was then the standard protocol, but by her second recurrence she moved to a clinical trial for IDEC C2B8, the research name for the drug later approved as Rituxan in 1997. In each case she either had a complete response, meaning disappearance of disease for at least three months, or a partial response, indicating a decrease in tumor size of at least 30 percent. [Outside of clinical trials, a partial response is defined as a reduction in tumor size of at least 50 percent.] Here is a rundown of Wendy’s treatments over the past two decades.
November 1990: DIAGNOSIS
[Stage 3 indolent non-Hodgkin’s lymphoma]
CURRENT STATUS: IN REMISSION